Morning Trend | Tigermed continues to weaken, can the key support withstand the emotional backlash?
Tigermed (3347.HK) has recently faced significant pressure, continuing to show weakness in early trading, with consecutive bearish candles indicating insufficient buying momentum in the market. The MACD indicator's death cross pattern persists, and the momentum histogram is diverging downward, with no signs of easing in the short-term downtrend. Over the past week, the stock price has fluctuated around HKD 48.00, with major funds showing an outflow trend, and there are few bargain-hunting buyers entering the market, leading to a cautious investor sentiment. The safety cushion is gradually being squeezed, and panic selling may emerge as support is tested; if it falls below HKD 47.00, panic selling in the market may intensify. From an industry perspective, the pharmaceutical services sector has recently shown significant divergence, lacking strong driving themes, leading to an overall increase in risk premium, with some funds choosing to retreat to safer investments. In the short term, if the HKD 48.00 area is lost again today, there is a risk that the stock price may fill the previous gap, exacerbating the bearish trend. If support holds successfully and trading volume improves, a brief structural rebound may occur, but the rebound's height will be limited by the downward moving average pressure, and speculative funds should enter and exit quickly. It is recommended to pay attention to MACD bullish divergence and volume reversal signals; if the trend shifts from a death cross to convergence, a light position trial may be considered. Overall, Tigermed currently has weak market confidence, and the emotional turning point has not yet been established, with a high risk of structural rebound failure. Investors should prioritize capital safety and position control, respond lightly to high volatility, and patiently wait for clear signs of strength before increasing positions
Tigermed (3347.HK) has recently faced significant pressure in its performance, continuing to show weakness in early trading, with consecutive bearish candlesticks indicating insufficient buying momentum in the market. The MACD indicator's death cross pattern persists, with the momentum histogram diverging downward, showing no signs of easing in the short-term downtrend. Over the past week, the stock price has fluctuated around HKD 48.00, with major funds showing signs of outflow, and there are few bargain-hunting buyers entering the market, leading to a cautious investor sentiment. The safety cushion is gradually being squeezed, and panic selling is emerging as support is tested; if it falls below HKD 47.00, panic selling in the market may intensify. From an industry perspective, the pharmaceutical services sector has recently shown significant divergence, lacking strong driving themes, leading to an overall increase in risk premium, with some funds choosing to retreat to safer investments. In the short term, if the price fails to hold the HKD 48.00 area again today, there is a risk of filling the previous gap, exacerbating the bearish trend. If support holds successfully and trading volume improves, a brief structural rebound may occur, but the height of the rebound will be limited by the downward moving average resistance, and speculative funds should enter and exit quickly. It is recommended to pay attention to MACD bullish divergence and volume reversal signals; if the trend shifts from a death cross to convergence, a light position trial may be considered. Overall, Tigermed currently has weak market confidence, and the emotional turning point has not yet been established, with a high risk of structural reversal; investors should prioritize capital safety and position control, respond lightly to high volatility, and patiently wait for clear signals of strength before increasing positions
